Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses Juvena’s "pipeline in a product" JUV-161 and plans to broaden into other disease indications.

Avidity Biosciences receives Japan MHLW’s orphan drug status for delpacibart etedesiran to treat myotonic dystrophy type 1: San Diego Thursday, April 10, 2025, 13:00 Hrs [IST] A ...

Avidity Biosciences, Inc.’s RNA share price has dipped by 7.10%, which has investors questioning if this is right time to buy ...

Avidity Biosciences, Inc. , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCstm), today announced that the Japan ...

Mexiletine appears to be safe and is likely an effective treatment for managing symptoms of myotonia (delayed muscle relaxation after a contraction) in people wit ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, ...

Building on initial awards totalling over £1.6m, a team of researchers are receiving further investment to explore the capabilities of quantum ...

Dyne Therapeutics, Inc.’s DYN share price has dipped by 12.10%, which has investors questioning if this is right time to buy.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 24th Annual ...

A University of Kansas student earned the title of Miss Wheelchair Kansas 2025 this month during the organization’s 20th ...

Myotonic dystrophy type 1 incurs high healthcare costs, driven by age and comorbidities like cardiac and respiratory issues. Early detection and integrated management of multisystemic ...